Intravenous Immunoglobulin (IVIG) from GC Biopharma.
Alyglo is a 10% IVIG product from GC Biopharma, FDA-approved for primary humoral immunodeficiency in adults. It is a newer addition to the IVIG product portfolio, offering an additional option for patients and providers when product availability or tolerability considerations are relevant.
Alyglo is FDA-approved for the following indications:
Alyglo is administered intravenously every three to four weeks, with infusion options at home, in our suite at Horizon Infusions, or at a partner ambulatory infusion center.
The manufacturer offers a patient support program — GC Biopharma Patient Support — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.alyglo.com.
Treatment with Alyglo is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Infusion logistics are coordinated through trusted partner infusion providers — including Horizon Infusions, where the practice is co-located — or arranged for home infusion when appropriate. The team handles scheduling, nursing coordination, and prior-authorization renewals.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.alyglo.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Alyglo is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.